"How long until this is running?" is the question every practice asks and almost nobody answers honestly. The clinical setup is fast and the commercial build is slow, so practices that measure readiness by equipment and training consistently believe they are three weeks from launch when they are four months from revenue.
A regenerative medicine service line typically takes two to four weeks to be clinically ready and three to six months to produce predictable revenue. The gap between those two numbers is the consultation and follow-up process, which is the part that determines whether the line works at all.
Two Different Timelines
Clinical readiness means you can safely and competently perform the procedure: sourcing arranged, provider trained or hired, space and handling sorted, structure reviewed. For a practice already performing guided injections this can be a few weeks. For one starting from nothing it is longer, but still measured in weeks.
Commercial readiness means you can reliably convert an interested patient into a paying one. That requires a consultation process, someone trained to run it, a proposal mechanism, follow-up that persists for weeks, and enough completed cases to know your real close rate.
Practices announce launch at clinical readiness and then spend months wondering why revenue is lumpy. The honest launch date is the second one.
A Realistic Month-by-Month
Month 1 — decide and set up. Structure and any hiring settled, sourcing arranged, indications chosen, pricing set. Nothing is being sold yet, and that is correct.
Month 2 — first conversations from your own charts. Review existing patients, run your first consultations, expect them to be uneven. The purpose of this month is not revenue, it is learning which objections actually come up and where your process breaks.
Month 3 — first cases close. Typically a handful, nearly all from the existing patient base. This is also when you get your first real close-rate number, which is the figure everything downstream depends on.
Months 4 to 6 — tighten, then spend. Fix what the first cases exposed, install follow-up sequences, and only now begin outside acquisition. You can finally calculate what you are able to pay for a lead because you know what a consultation converts at.
Months 6 to 12 — predictable volume. Acquisition channels measured against a known threshold, a trained closer, referral relationships beginning to contribute.
What Makes It Slower
Three things reliably add months.
Nobody owns the conversation. If consultations are handled by whoever is free, the process never improves because nobody is accountable for it. This is the single largest source of delay.
Advertising before converting. Practices that buy traffic before they can close spend the first quarter learning an expensive lesson and often conclude the category does not work. What did not work was selling a five-figure treatment with no sales process.
Treating the first slow months as failure. The decision cycle in this category runs weeks to months. A patient who inquires in week three may pay in week eleven. Practices that judge month two on revenue frequently kill something that was working.
What Makes It Faster
An existing patient base worked deliberately. This is the biggest accelerator available, and it costs nothing. Practices that run a proper chart review shorten time-to-first-case by a month or more.
Somebody who has closed before. Whether hired or trained, having one person who can competently run a five-figure conversation compresses the learning curve dramatically.
Narrow indications. Launching with one condition means one message, one candidacy standard, and one consultation to get right. Practices launching broadly take longer to get good at anything. The reasoning is in how to differentiate a clinic.
Budget for the Ramp, Not Just the Launch
The financial mistake is funding setup and assuming revenue starts immediately. Provider time, a coordinator, and software are being paid from month one while meaningful revenue arrives around month three and predictable revenue later than that.
Plan working capital for at least six months of that gap. Practices that run out of patience in month four usually run out of money first, and they abandon service lines that were on track. The model is in what it costs to add a regenerative medicine service line.
Milestones Worth Tracking Instead of Dates
Dates drift. Milestones tell you where you actually are.
First consultation run. First case closed. First case from outside the existing patient base. First month with a measured close rate over a defined threshold. First month where acquisition cost is under your allowable ceiling.
That last one is the real launch. Everything before it is validation, and a practice that hits it in month five is ahead of one that "launched" in month one and is still guessing.
Frequently Asked Questions
Can we be treating patients within a month?
Often yes clinically, especially if you already perform guided injections. Whether you have patients who have agreed to pay is a separate question, and that is the one that determines revenue.
When should we start advertising?
After you have closed several cases from your own patient base and know your close rate. Advertising into an unproven consultation process converts slowly and costs a lot to learn from.
How long before it is profitable?
Commonly six to twelve months, driven by how quickly the consultation process becomes reliable rather than by clinical readiness. Practices that validate internally first tend to reach it sooner.
Is it worth doing if we cannot commit six months?
Probably not. The decision cycle alone means the first cases take months to mature. A practice that needs revenue this quarter should fix conversion on what it already sells instead.
Want a realistic timeline for your practice? Book a free strategy call.